BETA
Suture-retention and skin-closure devices intended to distribute tension around surgical wounds.
SUTUREGARD Medical offers wound-closure adjuncts designed to spread suture tension over a wider skin area. Its website describes adhesive suture-retention devices and Interlock products used in orthopedic, vascular, plastic-surgery and dermatologic procedures. The company lists a Corvallis, Oregon contact address.
The portfolio includes products previously presented under the HEMIGARD name as well as current SUTUREGARD branding. Device records identify reviewed HEMIGARD retention devices as exempt from premarket submission. Exemption and FDA registration should not be described as a 510(k) clearance or evidence of clinical superiority.
Its commercial materials address surgeons, surgical facilities and purchasing teams, with case examples and publications supporting further review. Product-specific use instructions, duration of application and wound selection matter. Leadership and founding-date accounts conflict across older sources and the connection export, so unresolved titles and dates are not asserted as verified facts.
Reviewed HEMIGARD ASRD and Interlock device records identify exemption from premarket submission. Exact current-brand and model mapping remains incomplete. Exemption is not FDA approval; intended use, labeling and applicable exemption limitations still govern marketing. [1][2][12][9][10][3]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [7][5]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
Skin-surface device intended to distribute suture tension; exact current brand/model mapping remains under review. [9][1]
Exemption documentedCommercially offered; exact model and country availability should be confirmed with the manufacturer.
Retention-device family described in company materials and HEMIGARD Interlock device records. [9][2]
Exemption documentedCommercially offered; exact model and country availability should be confirmed with the manufacturer.
Commercial focus is surgeon adoption across specialties and wound-closure applications. Device listing establishes identity and exemption information, not comparative clinical effectiveness. [9][13]
Accessed 10/29/2026